Literature DB >> 10398825

The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography.

M P Stokkel1, C H Terhaard, G J Hordijk, P P van Rijk.   

Abstract

Primary tumors of the larynx and hypopharynx are preferably treated with high-dose radiation therapy. In these patients, it may be difficult to distinguish recurrent disease from post-treatment reactions. The aim of the present study was to assess the value of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) in the detection of local relapses of laryngeal or hypopharyngeal carcinoma after radiotherapy using a dual-head PET camera. Forty-eight patients (43 male, 5 female; mean age +/-SD, 61+/-9.5 years) with suspected recurrent laryngeal or hypopharyngeal cancer were prospectively studied. The mean interval between initial treatment and suspicion of recurrent disease was 14.6 months (range: 3-100 months). FDG dual-head PET was followed by endoscopy with or without biopsy under general anaesthesia within a period of 2 months in all patients. The mean period of follow-up after FDG dual-head PET was 13.7 months. In 19 out of 31 patients with focally increased uptake, tumour recurrence (mean diameter: 2.4 cm; range 0.4-6.5 cm) was found at initial endoscopy. In five patients recurrence was found during follow-up with a mean interval of 6.6 months. Seven patients had a false-positive study due to benign lesions or swallowing artefacts. In none of the patients with a normal PET study was tumour recurrence found during follow-up. The sensitivity and specificity of FDG dual-head PET were 100% and 71%, respectively. It is concluded that FDG dual-head PET is highly sensitive for the detection of local recurrence of laryngeal and hypopharyngeal carcinoma after radiotherapy. Some lesions were detected with a mean interval of 6.6 months before histological confirmation. In patients suspected of having recurrent laryngeal or hypopharyngeal cancer in whom FDG-PET is negative, endoscopy may be omitted for at least 6 months and possibly for up to 1 year.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398825     DOI: 10.1007/s002590050448

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  12 in total

1.  Evaluation of head and neck squamous cell carcinoma after treatment.

Authors:  Suresh K Mukherji; Gregory T Wolf
Journal:  AJNR Am J Neuroradiol       Date:  2003-10       Impact factor: 3.825

Review 2.  Functional imaging in head and neck cancer.

Authors:  David I Kutler; Richard J Wong; Dennis H Kraus
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

3.  Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment.

Authors:  Philippe Robin; Ronan Abgral; Gérald Valette; Pierre-Yves Le Roux; Nathalie Keromnes; Jean Rousset; Gaël Potard; Xavier Palard; Rémi Marianowski; Pierre-Yves Salaun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-29       Impact factor: 9.236

Review 4.  Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma.

Authors:  Antoine Digonnet; Marc Hamoir; Guy Andry; Missak Haigentz; Robert P Takes; Carl E Silver; Dana M Hartl; Primož Strojan; Alessandra Rinaldo; Remco de Bree; Andreas Dietz; Vincent Grégoire; Vinidh Paleri; Johannes A Langendijk; Vincent Vander Poorten; Michael L Hinni; Juan P Rodrigo; Carlos Suárez; William M Mendenhall; Jochen A Werner; Eric M Genden; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-13       Impact factor: 2.503

5.  Newer imaging techniques in head and neck cancer.

Authors:  Nilendu C Purandare; Venkatesh Rangarajan
Journal:  Indian J Surg Oncol       Date:  2010-11-21

6.  [18F]FDG imaging of head and neck tumours: comparison of hybrid PET and morphological methods.

Authors:  S Dresel; J Grammerstorff; K Schwenzer; K Brinkbäumer; R Schmid; T Pfluger; K Hahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-09       Impact factor: 9.236

7.  Usefulness of esophagogastroduodenoscopy and 18F-fluorodeoxyglucose positron-emission tomography in detecting synchronous multiple primary cancers with oral cancer.

Authors:  Naomi Ishibashi-Kanno; Kenji Yamagata; Fumihiko Uchida; Shogo Hasegawa; Toru Yanagawa; Hiroki Bukawa
Journal:  Oral Maxillofac Surg       Date:  2017-08-31

8.  Staging primary head and neck cancers with (18)F-FDG PET/CT: is intravenous contrast administration really necessary?

Authors:  Keisuke Yoshida; Akiko Suzuki; Toshiyuki Nagashima; Jin Lee; Choichi Horiuchi; Mamoru Tsukuda; Tomio Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-08       Impact factor: 9.236

Review 9.  Clinical applications of tumor volume measurements for predicting outcome in patients with squamous cell carcinoma of the upper aerodigestive tract.

Authors:  Suresh K Mukherji; Ilona M Schmalfuss; Jonas Castelijns; Anthony A Mancuso
Journal:  AJNR Am J Neuroradiol       Date:  2004-09       Impact factor: 3.825

Review 10.  Post-therapeutic surveillance schedule for oral cancer: is there agreement?

Authors:  Guicai Liu; Eric J Dierks; R Bryan Bell; Tuan G Bui; Bryce E Potter
Journal:  Oral Maxillofac Surg       Date:  2012-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.